JPWO2020005807A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020005807A5
JPWO2020005807A5 JP2020573003A JP2020573003A JPWO2020005807A5 JP WO2020005807 A5 JPWO2020005807 A5 JP WO2020005807A5 JP 2020573003 A JP2020573003 A JP 2020573003A JP 2020573003 A JP2020573003 A JP 2020573003A JP WO2020005807 A5 JPWO2020005807 A5 JP WO2020005807A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
carbamate
acid
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528470A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038677 external-priority patent/WO2020005807A1/en
Publication of JP2021528470A publication Critical patent/JP2021528470A/ja
Publication of JPWO2020005807A5 publication Critical patent/JPWO2020005807A5/ja
Pending legal-status Critical Current

Links

JP2020573003A 2018-06-25 2019-06-24 Taireファミリーキナーゼインヒビターおよびそれらの使用 Pending JP2021528470A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689551P 2018-06-25 2018-06-25
US62/689,551 2018-06-25
PCT/US2019/038677 WO2020005807A1 (en) 2018-06-25 2019-06-24 Taire family kinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2021528470A JP2021528470A (ja) 2021-10-21
JPWO2020005807A5 true JPWO2020005807A5 (de) 2024-01-12

Family

ID=68986049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573003A Pending JP2021528470A (ja) 2018-06-25 2019-06-24 Taireファミリーキナーゼインヒビターおよびそれらの使用

Country Status (7)

Country Link
US (1) US20220169631A9 (de)
EP (1) EP3810132A4 (de)
JP (1) JP2021528470A (de)
CN (1) CN112367991A (de)
AU (1) AU2019295632A1 (de)
CA (1) CA3099763A1 (de)
WO (1) WO2020005807A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
CN111848579B (zh) * 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药
CN114404591B (zh) * 2022-01-28 2023-03-17 深圳市泰尔康生物医药科技有限公司 Cdk14作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
WO2023192534A1 (en) * 2022-03-30 2023-10-05 Ohio State Innovation Foundation Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereof
WO2023227125A1 (zh) * 2022-05-26 2023-11-30 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265452T3 (es) * 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
WO2005012256A1 (en) * 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
EP1847531A4 (de) * 2005-02-09 2009-04-22 Takeda Pharmaceutical Pyrazolverbindung
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP2046327A1 (de) * 2006-07-21 2009-04-15 Astex Therapeutics Limited Medizinische verwendung von cyclinabhängigen kinasehemmern
KR100923540B1 (ko) * 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
BR112017013677B1 (pt) * 2015-02-05 2023-11-21 Merck Patent Gmbh Compostos macrocíclicos como inibidores de irak1/4, seu processo de fabricação e seus usos, e composições farmacêuticas
WO2016193939A1 (en) * 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
CN107235906B (zh) * 2017-06-28 2020-05-01 郑州大学第一附属医院 一组吡唑酰胺类衍生物及其应用
CN107686477B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 作为cdk4/6抑制剂的新型化合物及其应用

Similar Documents

Publication Publication Date Title
US9926291B2 (en) Synthesis of thiohydantoins
JP2015221832A5 (de)
JP2011162566A5 (de)
ES2664872T3 (es) Moduladores PRPK-TPRKB y sus usos
US7763735B2 (en) Synthesis of enone intermediate
US20190000860A1 (en) Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20060287520A1 (en) Synthesis of salinosporamide A and analogues thereof
US11931346B2 (en) Uses of 4′-desferrithiocin analogs
US20110263569A1 (en) Ryanodine channel binders and uses thereof
US20140323534A1 (en) Uses of 3'-desferrithiocin analogs
WO2008144507A2 (en) Spirooxindole inhibitors of aurora kinase
JPWO2020005807A5 (de)
US20220152036A1 (en) COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA
US8715621B2 (en) Radical polarizing agents for dynamic nuclear polarization